Skip to main content
Terug
DNTH logo

Dianthus Therapeutics, Inc.

Datakwaliteit: 100%
DNTH
NASDAQ Healthcare Biotechnology
€ 78,55
▼ € 0,77 (-0,97%)
Marktkapitalisatie: 2,84B
Dagbereik
€ 76,42 € 80,28
52-Weeksbereik
€ 13,37 € 88,02
Volume
852.060
50D / 200D Gem.
€ 56,34 / € 37,05
Vorige Slotkoers
€ 79,32

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -17,5 0,3
P/B 5,8 2,9
ROE % -38,4 3,7
Net Margin % -7973,3 3,8
Rev Growth 5Y % 8,4 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 101,00 +28.6%
Low: € 55,00 High: € 145,00
Forward WPA
-€ 4,30
Omzet Sch.
1,5 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 2,60
-€ 0,25 – € 10,68
670 M 4
FY2029 -€ 3,70
-€ 15,21 – € 0,36
200 M 4
FY2028 -€ 5,47
-€ 8,72 – -€ 3,31
19 M 11

Belangrijkste Punten

Revenue grew 8,37% annually over 5 years — modest growth
Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -129,27M
Revenue growth is decelerating — 1Y growth trails 5Y average by 75,72%

Groei

Revenue Growth (5Y)
8,37%
Revenue (1Y)-67,35%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-38,38%
ROIC-26,97%
Net Margin-7973,33%
Op. Margin-8739,34%

Veiligheid

Debt / Equity
0,00
Current Ratio13,32
Interest Coverage0,00

Waardering

P/E Ratio
-17,52
P/B Ratio5,76
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -67,35% Revenue Growth (3Y) -15,12%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 8,37% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 2,04M Net Income (TTM) -162,34M
ROE -38,38% ROA -30,58%
Gross Margin 100,00% Operating Margin -8739,34%
Net Margin -7973,33% Free Cash Flow (TTM) -129,27M
ROIC -26,97% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 13,32
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -17,52 P/B Ratio 5,76
P/S Ratio 1397,07 PEG Ratio -0,15
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 2,84B Enterprise Value 2,79B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,04M 6,24M 2,83M 6,42M 1,48M
Net Income -162,34M -84,97M -43,56M -28,48M -13,11M
EPS (Diluted) -4,20 -2,55 -8,45 -7,60 -3,82
Gross Profit 2,04M 6,24M 2,83M 6,42M 1,48M
Operating Income -177,93M -101,86M -48,17M -29,71M -13,09M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 530,92M 374,01M 179,41M 83,11M 189,93M
Total Liabilities 37,52M 21,53M 10,54M 9,45M 17,26M
Shareholders' Equity 493,40M 352,48M 168,87M 73,66M 172,67M
Total Debt 1,39M 1,49M 585.000,0 788.000,0 0,0
Cash & Equivalents 51,09M 22,79M 132,33M 15,37M 131,65M
Current Assets 409,44M 280,90M 177,45M 82,03M 180,69M
Current Liabilities 30,73M 18,45M 9,63M 8,23M 10,86M